Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Jun 14;7(3):75-78.
doi: 10.31547/bct-2024-005. eCollection 2024 Aug 25.

Long-term remissions with Gilteritinib in early relapse after allogeneic stem cell transplantation of FLT3/NPM1 mutated acute myeloid leukemia

E Tamellini  1 , M Sorio  2 , A Andreini  2 , C Tecchio  1   2 , G Nadali  2 , A Bernardelli  2 , I Ferrarini  1   2 , L Crosera  1   2 , A Vatteroni  1   2 , C Simio  1   2 , F Benedetti  2 , M Krampera  1   2 , I Tanasi  2
Affiliations
Case Reports

Long-term remissions with Gilteritinib in early relapse after allogeneic stem cell transplantation of FLT3/NPM1 mutated acute myeloid leukemia

E Tamellini et al. Blood Cell Ther. .

Abstract

Early post-allogeneic hematopoietic stem cell transplantation (allo-HSCT) relapse in patients with acute myeloid leukemia (AML) has an almost invariably dismal prognosis. Recent studies have demonstrated that FLT3 inhibition enhances the graft-versus-leukemia effect in vitro and in vivo. Thus, FLT-3 inhibitors may be viable treatment options in this setting. Here, we report three patients with FLT3 and NPM1 mutated AML who relapsed early after allo-HSCT and were treated with gilteritinib (associated with donor lymphocyte Infusion in two patients) to achieve long-term remission without a second transplantation.

Keywords: FLT3-inhibitors; acute myeloid leukemia; post-transplant relapse.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. Disclosure forms provided by the authors are available on the website.

Figures

Figure 1.
Figure 1.. Overview of the patient's medical history.
AML, Acute Myeloid Leukemia; CR/CRi, Complete Remission/Complete Remission with incomplete hematologic recovery; Allo-HSCT, Allogeneic Hematopoietic Stem Cell Transplantation; DLI, Donor Lymphocyte Infusions
See this image and copyright information in PMC

References

    1. Bejanyan N, Weisdorf DJ, Logan BR, Wang HL, Devine SM, de Lima M, et al. Survival of Patients with Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Study. Biol Blood Marrow Transplant. 2015; 21: 454-9. - PMC - PubMed
    1. Zhang Z, Hasegawa Y, Hashimoto D, Senjo H, Kikuchi R, Chen X, et al. Gilteritinib enhances graft-versus-leukemia effects against FLT3-ITD mutant leukemia after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2022; 57: 775-80. - PubMed
    1. Mathew NR, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, et al. Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nat Med. 2018; 24: 282-91. - PMC - PubMed
    1. Biavasco F, Zeiser R. FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation. Int J Hematol. 2022; 116: 341-50. - PMC - PubMed
    1. Sorà F, Chiusolo P, Metafuni E, Bellesi S, Giammarco S, Laurenti L, et al. Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3/ITD+) acute myeloid leukemia after allogenic stem cell transplantation. Leuk Res. 2011; 35: 422-3. - PubMed

Publication types

LinkOut - more resources